Abstract: A compound having a BCL-XL protein degradation function as shown in Formula I and a use thereof in preparation of a drug for diseases associated with BCL-XL activity.

Abstract: The invention provides a preparation method of a nickel-based wrought superalloy wheel disk forging used at high temperature, in which the alloy has high content of solution strengthening elements W, Mo and strengthening phase ?? phase forming elements Al, Ti, Nb and ?? phase content reaches 55-65%. In view of a series of technical problems caused by high ?? phase to alloy smelting and forging, the high-temperature stress relief annealing, low-temperature stress relief annealing process of steel ingot and high temperature homogenizing annealing of steel bar were proposed by optimizing the thermal process of wheel disk forging and controlling the precipitation and dissolution of ?? phase.

Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound, a metabolite or a prodrug thereof, a pharmaceutical composition and a pill container comprising same, a preparation method therefor, and the use thereof in the preparation of drugs for preventing or treating STING-mediated related diseases.

Abstract: The present invention belongs to the field of pharmaceuticals, and particularly relates to a tricyclic compound, a method for preparing same, and use thereof. In particular, the present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, a method for preparing same, a pharmaceutical composition comprising same, and uses thereof.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: The present application relates to the field of superalloy, disclosing a method for internal stress regulation in superalloy disk forgings by pre-spinning. The method includes: Step S1, determining a target revolution for regulating internal stress in the disk forgings, and determining a target deformation magnitude of plastic deformation required for regulating the internal stress by the pre-spinning of the disk forgings; and Step S2, performing the pre-spinning of the disk forgings by the target revolution, monitoring a deformation magnitude of the disk forgings, and stopping the pre-spinning when a monitored deformation magnitude of the disk forgings reaches the target deformation magnitude.

Abstract: Provided in the present application are an antibody-drug conjugate, and a preparation method therefor and the use thereof. The antibody drug conjugate has a structure as represented by the formula Ab-[M-L-E-D]x, and the drug is selected from an anti-tubulin agent, a DNA intercalator, a DNA topoisomerase inhibitor and a RNA polymerase inhibitor. The prepared antibody-drug conjugate has a better drug-to-antibody ratio, and has a good targeted killing effect on colon cancer and non-small cell lung cancer (for example, lung adenocarcinoma).

Abstract: The present invention relates to a chemical coupling linker and use thereof, and a bioactive conjugate prepared by the chemical coupling linker. The present invention also relates to use of the bioactive conjugate in the preparation of a drug for the prevention or treatment of tumor diseases.

Abstract: The present invention relates to a Camptothecin compound having anti-tumor activity, a preparation method therefor, and an application thereof. Specifically, the present invention relates to a compound as shown below or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof.

Abstract: Provided herein are bioactive molecule conjugates, preparation methods and use thereof, particularly bioactive molecule conjugates (such as antibody-drug conjugates and small molecule drug conjugates) obtained by improved coupling of a drug and a targeting moiety, as well as their preparation method and use for the treatment of a disease associated with an abnormal cell activity.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: Related is an anti-CLDN 18.2 antibody-drug conjugate, preparation method and use thereof. The antibody-drug conjugate and the composition thereof is capable of effectively binding CLDN 18.2 and inhibiting the growth of Claudin 18.2 positive tumors. Further related is a pharmaceutical composition comprising the antibody-drug conjugate or the composition, and use of the pharmaceutical composition in the preparation of a medicament for preventing and/or treating tumors.

Abstract: The present invention relates to an aryl amide compound of formula (I?), a pharmaceutical composition comprising same, a preparation method therefor, and the use thereof for preventing or treating tumor-related diseases or conditions.

Abstract: The present invention relates to a pyrazole compound and a preparation method therefor and a use thereof. In particular, the present invention relates to a compound shown in Formula I, a pharmaceutical composition containing same or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof.

Abstract: Provided are a salt and a crystal form of a pyrimidine compound, and preparation methods therefor. Specifically, provided are a salt and a crystal form of a compound I, including a crystal form of the salt, and preparation methods therefor.

Abstract: The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrazine compound, a pharmaceutical composition comprising same, and the use thereof. In particular, the present invention relates to a compound with the structure of formula (I), which exhibits a good SHP2 inhibiting activity, and can act as an efficient SHP2 inhibitor for preventing and/or treating SHP2-related diseases.

Abstract: The present application relates to the field of superalloy, disclosing a method for internal stress regulation in superalloy disk forgings by pre-spinning. The method includes: Step S1, determining a target revolution for regulating internal stress in the disk forgings, and determining a target deformation magnitude of plastic deformation required for regulating the internal stress by the pre-spinning of the disk forgings; and Step S2, performing the pre-spinning of the disk forgings by the target revolution, monitoring a deformation magnitude of the disk forgings, and stopping the pre-spinning when a monitored deformation magnitude of the disk forgings reaches the target deformation magnitude.

Abstract: Disclosed are a solid form of (E)-3-((R)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acrylic acid, a preparation method therefor, a pharmaceutical composition comprising same, and the use thereof in the preparation of drugs for preventing or treating viral diseases.

Abstract: The present application relates to a solid form of a compound of Formula (I), a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and uses of the solid form in preparing a medicament for treating or preventing peroxisome proliferator-activated receptor (PPAR)-related diseases such as nonalcoholic fatty liver disease (NAFLD).

Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound, a metabolite or a prodrug thereof, a pharmaceutical composition and a pill container comprising same, a preparation method therefor, and the use thereof in the preparation of drugs for preventing or treating STING-mediated related diseases.